460 Stock Overview
An investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical and medical aesthetic products in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 460 from our risk checks.
Sihuan Pharmaceutical Holdings Group Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.57 |
| 52 Week High | HK$0.80 |
| 52 Week Low | HK$0.49 |
| Beta | 0.66 |
| 1 Month Change | 1.79% |
| 3 Month Change | -1.72% |
| 1 Year Change | -20.83% |
| 3 Year Change | -85.00% |
| 5 Year Change | -68.33% |
| Change since IPO | -90.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 460 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -8.1% | -5.8% | -3.1% |
| 1Y | -20.8% | -7.7% | 2.7% |
Return vs Industry: 460 underperformed the Hong Kong Pharmaceuticals industry which returned -7.7% over the past year.
Return vs Market: 460 underperformed the Hong Kong Market which returned 2.7% over the past year.
Price Volatility
| 460 volatility | |
|---|---|
| 460 Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 15.6% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 460 has not had significant price volatility in the past 3 months.
Volatility Over Time: 460's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 2,872 | Weicheng Guo | www.sihuanpharm.com |
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical and medical aesthetic products in the People’s Republic of China. The company operates through three segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. It offers filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care, and others, as well as non- or minimally invasive medical aesthetics comprehensive solutions.
Sihuan Pharmaceutical Holdings Group Ltd. Fundamentals Summary
| 460 fundamental statistics | |
|---|---|
| Market cap | HK$5.29b |
| Earnings (TTM) | -HK$58.23m |
| Revenue (TTM) | HK$2.01b |
2.6x
P/S Ratio-90.9x
P/E RatioIs 460 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 460 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.86b |
| Cost of Revenue | CN¥564.90m |
| Gross Profit | CN¥1.30b |
| Other Expenses | CN¥1.35b |
| Earnings | -CN¥54.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0058 |
| Gross Margin | 69.64% |
| Net Profit Margin | -2.90% |
| Debt/Equity Ratio | 22.9% |
How did 460 perform over the long term?
See historical performance and comparison